The Department is doing everything appropriate to prepare for leaving the European Union. We want to reassure patients that our plans should ensure the uninterrupted supply of medicines and medical products, including medical radioisotopes, once we have left the EU.<\/p>
The Department\u2019s plans include implementing a multi-layered approach to mitigate potential disruption to supply, which consists of stockpiling where possible, securing freight capacity, changing or clarifying regulatory requirements, procuring additional warehousing, working closely with industry to improve trader readiness and putting in place the National Supply Disruption Response to manage potential shortages. Further details can be found at the following link:<\/p>
https://www.gov.uk/government/news/medicines-and-medical-products-supply-government-updates-no-deal-brexit-plans<\/a>.<\/p> The supply of medical radioisotopes is being handled by dedicated officials, in collaboration with Devolved Administrations, the Crown Dependencies and Overseas Territories, as these products have particularly short shelf lives and therefore cannot be stockpiled, as well as having complex transport requirements given the radioactivity involved.<\/p> <\/p> The Department, together with other Government Departments and representatives from industry (suppliers and couriers), has also successfully completed an operational testing exercise to help to ensure the uninterrupted flow of medical radioisotopes if the UK leaves the EU without a deal. This has allowed us to test the resilience of the supply chain arrangements for medical radioisotopes.<\/p> <\/p> Prices of medicines often vary due to a wide variety of factors under normal conditions and there is no evidence that the cost of medicines to the NHS are outside of expected ranges. We will continue to monitor this. <\/em>The UK Government is working closely with the Devolved Administrations, the NHS and suppliers of medical radioisotopes to monitor the costs of radiopharmaceuticals to the NHS in 2019-20.<\/p> <\/p> <\/p> <\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4362", "label" : {"_value" : "Biography information for Edward Argar"}
}
, "answeringMemberConstituency" : {"_value" : "Charnwood"}
, "answeringMemberPrinted" : {"_value" : "Edward Argar"}
, "dateOfAnswer" : {"_value" : "2019-10-21", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "402"}
, {"_value" : "403"}
, {"_value" : "405"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-10-21T13:06:43.637Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-10-15", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Radioisotopes: Imports"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the August 2019 British Nuclear Medicine Society's open letter to the Prime Minister on radioisotope delivery, what assessment his Department has made of the effect on the costs of radioisotope delivery of the UK leaving the EU without a deal.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/151", "label" : {"_value" : "Biography information for Tom Brake"}
}
, "tablingMemberConstituency" : {"_value" : "Carshalton and Wallington"}
, "tablingMemberPrinted" : [{"_value" : "Tom Brake"}
], "uin" : "400"}
, {"_about" : "http://data.parliament.uk/resources/1149210", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1149210/answer", "answerText" : {"_value" : " The number of people registered with diabetes at a general practitioner (GP) practice in 2017-18 by clinical commissioning group and diabetes type in England can be found in the attached table.<\/p> The Department is doing everything appropriate to prepare for leaving the European Union. We want to reassure patients that our plans should help to ensure the uninterrupted supply of medicines and medical products, including insulin, once we have left the EU.<\/p> As part of our EU exit preparations, we are implementing a multi-layered approach to mitigate potential disruption to supply, which consists of stockpiling where possible, securing freight capacity, changing or clarifying regulatory requirements, procuring additional warehousing, working closely with industry to improve trader readiness and putting in place the National Supply Disruption Response to manage potential shortages.<\/p> All three suppliers of insulin have publicly stated that they have significantly increased their United Kingdom stockpiles, and have met the Government request that they hold at least six weeks\u2019 worth of extra stock in addition to their usual operational stocks.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"}
}
, "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"}
, "answeringMemberPrinted" : {"_value" : "Jo Churchill"}
, "attachment" : {"_about" : "http://data.parliament.uk/resources/1149210/answer/attachment/1", "fileName" : {"_value" : "PQ401England CCG level.docx"}
, "title" : "PQ401 table"}
, "dateOfAnswer" : {"_value" : "2019-10-23", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-10-23T16:56:42.707Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-10-15", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Diabetes"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to research conducted by 38 degrees showing that 571 people in Carshalton and Wallington have type 1 diabetes and rely on daily insulin, what assessment his Department has made of the distribution and number of diabetes sufferers in the UK; and what steps his department has taken to secure undisrupted supply of insulin across the UK in the event of the UK leaving the EU without a deal.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/151", "label" : {"_value" : "Biography information for Tom Brake"}
}
, "tablingMemberConstituency" : {"_value" : "Carshalton and Wallington"}
, "tablingMemberPrinted" : [{"_value" : "Tom Brake"}
], "uin" : "401"}
, {"_about" : "http://data.parliament.uk/resources/1149361", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1149361/answer", "answerText" : {"_value" : " The Department is doing everything appropriate to prepare for leaving the European Union. We want to reassure patients that our plans should ensure the uninterrupted supply of medicines and medical products, including medical radioisotopes, once we have left the EU.<\/p> The Department\u2019s plans include implementing a multi-layered approach to mitigate potential disruption to supply, which consists of stockpiling where possible, securing freight capacity, changing or clarifying regulatory requirements, procuring additional warehousing, working closely with industry to improve trader readiness and putting in place the National Supply Disruption Response to manage potential shortages. Further details can be found at the following link:<\/p> https://www.gov.uk/government/news/medicines-and-medical-products-supply-government-updates-no-deal-brexit-plans<\/a>.<\/p> The supply of medical radioisotopes is being handled by dedicated officials, in collaboration with Devolved Administrations, the Crown Dependencies and Overseas Territories, as these products have particularly short shelf lives and therefore cannot be stockpiled, as well as having complex transport requirements given the radioactivity involved.<\/p> <\/p> The Department, together with other Government Departments and representatives from industry (suppliers and couriers), has also successfully completed an operational testing exercise to help to ensure the uninterrupted flow of medical radioisotopes if the UK leaves the EU without a deal. This has allowed us to test the resilience of the supply chain arrangements for medical radioisotopes.<\/p> <\/p> Prices of medicines often vary due to a wide variety of factors under normal conditions and there is no evidence that the cost of medicines to the NHS are outside of expected ranges. We will continue to monitor this. <\/em>The UK Government is working closely with the Devolved Administrations, the NHS and suppliers of medical radioisotopes to monitor the costs of radiopharmaceuticals to the NHS in 2019-20.<\/p> <\/p> <\/p> <\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4362", "label" : {"_value" : "Biography information for Edward Argar"}
}
, "answeringMemberConstituency" : {"_value" : "Charnwood"}
, "answeringMemberPrinted" : {"_value" : "Edward Argar"}
, "dateOfAnswer" : {"_value" : "2019-10-21", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "400"}
, {"_value" : "403"}
, {"_value" : "405"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-10-21T13:06:43.693Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-10-15", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Radioisotopes: Imports"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the implications for his Department's policies of the matters raised in the joint letter of 1 August 2019 from the British Nuclear Medicine Society and the Royal College of Radiologists to the Prime Minister entitled continued supply of medical radioisotopes in the event of a no-deal Brexit.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/151", "label" : {"_value" : "Biography information for Tom Brake"}
}
, "tablingMemberConstituency" : {"_value" : "Carshalton and Wallington"}
, "tablingMemberPrinted" : [{"_value" : "Tom Brake"}
], "uin" : "402"}
, {"_about" : "http://data.parliament.uk/resources/1149365", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1149365/answer", "answerText" : {"_value" : " The Department is doing everything appropriate to prepare for leaving the European Union. We want to reassure patients that our plans should ensure the uninterrupted supply of medicines and medical products, including medical radioisotopes, once we have left the EU.<\/p> The Department\u2019s plans include implementing a multi-layered approach to mitigate potential disruption to supply, which consists of stockpiling where possible, securing freight capacity, changing or clarifying regulatory requirements, procuring additional warehousing, working closely with industry to improve trader readiness and putting in place the National Supply Disruption Response to manage potential shortages. Further details can be found at the following link:<\/p>